Naslov
Trichiasis as a result of docetaxel chemotherapy for metastatic prostate cancer

Autori
Raguž, Jelena ; Vuković, Petra ; Marinčić, Iva ; Vincelj, Nikolina ; Krstić, Chiara ; Žepić, Monika ; Šahbazović, Ana ; Šeparović, Robert

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
Libri oncologici / Vrdoljak, Danko Velimir ; Vrbanec, Damir ; Tečić Vuger, Ana - Zagreb : Klinički bolnički centar Sestre milosrdnice, 2017, 70-70

Skup
1st Regional Congress of Medical Oncology and 1st Regional Congress of Oncology Pharmacy

Mjesto i datum
Dubrovnik, Hrvatska, 04.05.2017. - 07.05.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
docetaxel, side-effects, trichiasis, metastatic prostate cancer

Sažetak
Docetaxel is a chemotherapeutic agent from tihe class of taxanes which works by disrupting microtubule function to inhibit cell division. Docetaxel has been proven as a potent agent in treatment of various solid malignancies, including metastatic prostate cancer. Most adverse events associated with the use of docetaxel have been well documented and are expected, alopecia beeing at the top of the list. Patients are informed to expect not only hair loss, but also loss of ovearll body hair, including eyebrows and eyelashes. Trichiasis is an eyelid abnormality in which the eyelashes are misdirected and grow inwards toward the eye. Those inward-turning lashes rub against the cornea the inner surface of the eyelids which leads to eye irritation, swelling and redness and in severe cases to scarring of the cornea and vision impairment. A 62-year old male with no previous comorbidities was diagnosed with prostate cancer after a routine screeing discovered elevated PSA 14, 6. After biopsy and imaging the patient was classifi ed as intermediate risk based upon his Gleason score 7 (4+3), and PSA level and underwent radical prostatectomy. PHD was adenocarcinoma, GS7, meta lymphonodi, pT3bpN1M0. After surgery the patient received adjuvant radiotherapy in combination with ADT that lasted for 3 years. In 4/2011 the patient underwent orchidectomy on the count of biochemical relaps of the disease. He continued with ADT, Kalufar 5 mg. The patient was stabile untill 7/2014 when the PSA levels begin to rise, although he had no symptoms and was in overall good health. In 10/2014 PSA was 32, 6 and imaging methods (CT and PET scan) showed multiple metatstic lymph nodes and multidisciplinary team suggested chomotherapy with docetaxel which he started in11/2014 and completed in 7/2015. After 2 cycles of chemotherapy the patient lost most of his hair, including eyelashes wich didn’t grow back during the 10 cycles of docetaxel he received. 6-8 weeks after completing chemotherapy the patient started complaining of eye iritation, extensive lacrimation and blurred vison, especially on the left eye. He went for an ophtalmological exam and the diagnosis was trichiasis l. sin et dex susp. The ophtalmologist recommended the patient do eyelash epilation and ordered a checkup 4 weeks later to confi rm the diagnosis. After the confi rmation, the patient continued with mechanical eyelash epilation every 2-3 months. On the last checkup in 12/2016 the ophtalmologist suggested electroepilation as a permanent solution. Although docetaxel has been reported to cause itching, puffi ness, or swelling of the eyelids and loss of eyelashes is very common among patients recieveng this chemotherapy, this specifi c side effect has not been seen among our patients. It is important to keep in mind that chometherapeutics can cause signifi cant impairment in quality of life long after their last dose has been applied.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA